5. References

  1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2022. Accessed July 10, 2022.
  2. IMB Micromedex® DRUGDEX® (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed July 10, 2022.
  3. Dulaglutide subcutaneous injection (Trulicity®) package insert. Eli Lilly and Company, June 2022.
  4. Exenatide regular-release (Byetta®) package insert. AstraZeneca Pharmaceuticals, June 2022.
  5. Exenatide extended-release (Bydureon BCise®) package insert. AstraZeneca Pharmaceuticals, June 2022.
  6. Liraglutide subcutaneous injection (Victoza®) package insert. Novo Nordisk, June 2022.
  7. Liraglutide subcutaneous injection (Saxenda®) package insert. Novo Nordisk, June 2022.
  8. Lixisenatide subcutaneous injection (Adlyxin™) package insert. Sanofi-Aventis, June 2022.
  9. Semaglutide subcutaneous injection (Ozempic®) package insert. Novo Nordisk, March 2022.
  10. Semaglutide subcutaneous injection (Wegovy®) package insert. Novo Nordisk, June 2022.
  11. Semaglutide oral tablets (Rybelsus®) package insert. Novo Nordisk, June 2022.
  12. Tirzepatide subcutaneous injection (Mounjaro®) package insert. Eli Lilly and Company, May 2022.
  13. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes -2022. Diabetes Care. 2022;45(Suppl. 1):S125–S143.
  14. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2019;381(9):841-851.
  15. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes -2022. Diabetes Care. 2022;45(Suppl. 1):S144–S174.
  16. Ard J, Fitch A, Fruh S, Herman L. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Adv Ther. 2021 Jun;38(6):2821-2839.